Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024

Lord Hanson of Flint Excerpts

Tuesday 22nd October 2024 Grand Committee

Moved by

[Lord Hanson of Flint]

That the Grand Committee do consider the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024.

Relevant document: 3rd Report from Secondary Legislation Scrutiny Committee

[The Minister of State, Home Office (Lord Hanson of Flint) (Lab)]

My Lords, this order was laid before Parliament on 2 September. I thank the Advisory Council on the Misuse of Drugs, which I shall, for the purposes of brevity, call the ACMD from here on in, for its detailed and thorough advice, which has informed this draft order.

The purpose of this draft order is to amend Schedule 2 to the Misuse of Drugs Act, known as the MDA. The draft order will control six substances, as well as introduce a generic definition for nitazenes, as class A drugs and control 16 substances as class C drugs. The draft order will also make an amendment to an existing class B drug to give further clarity by adding an additional common name and its International Union of Pure and Applied Chemistry name to its entry.

I turn to 2-methyl-AP-237 and closely related substances. New synthetic opioids remain a current international and domestic public health threat. The ACMD has reported that, as with traditional opioids such as heroin, these can lead to dose-dependent adverse effects, including overdose risks, as well as the high potential for addiction and dependence. One of the 22 substances that I mentioned, 2-methyl-AP-237, was added to Schedule 1 to the Single Convention on Narcotic Drugs 1961 following the 66th session of the United Nations Commission on Narcotic Drugs. The UK is a signatory to that—I hope that Members have followed me so far—and we have an obligation to consider its introduction under domestic legislation.

On 27 March, the ACMD issued a report which considered the harms of 2-methyl-AP-237 but also provided advice to Ministers on closely related acyl piperazine opioids. The ACMD also noted the likelihood of further increases in their prevalence, as well as the potential health and social harms associated with specific acyl piperazine opioids. Following the recommendation from the ACMD, this draft order seeks to control four named acyl piperazine opioids and two chemically bridged acyl piperazine derivatives, which include 2-methyl-AP-237, as class A drugs under the MDA.

Under the MDA, there are several named nitazenes—another form of synthetic opioid—that are already listed as class A drugs. However, more needs to be done to reduce the opportunity for criminals to circumvent existing controls by making minor alterations to the chemical structure of these named drugs under control. As such, with this order we are trying to introduce a generic definition for nitazenes that has been recommended by the ACMD. The purpose of this is to future-proof the legislation by covering known and predicted variants likely to present a significant risk to health. The ACMD has already published four updates to address new structurally related compounds under the definition. As such, the draft order is designed to introduce a generic definition for nitazenes as a class A drug under the MDA.

I add for the Grand Committee’s consideration that many known benzodiazepines are used for medicinal purposes in the UK for the treatment of anxiety, insomnia and epilepsy, but more recently there has been an increase in the non-medical use of novel benzodiazepines and related compounds, which have been associated with significant health harms, including an increase in annual numbers of deaths where a benzodiazepine has been implicated.

The ACMD reported on benzodiazepines in 2020 but has since provided further advice on substances that are not controlled under the MDA. In the report dated March 2024—it obviously went to the previous Government—the ACMD recommended 15 benzo- diazepines for control, none of which is licensed as a medicine in the UK. As such, this draft order seeks to control those 15 benzodiazepines and related compounds as class C drugs under the MDA, in line with the ACMD’s advice.

We have seen an increase in the illicit use of xylazine, a non-opioid tranquiliser that has been approved for use in veterinary practice. Xylazine is being used to adulterate illicitly manufactured opioids, such as fentanyl, to produce a mixture known as “tranq” in the USA. In combination with other sedatives, it can dangerously lower a person’s level of consciousness. Again, these are recommendations to me, the ministry and the Home Office, and therefore, via the Home Office, to this House. The ACMD has recommended that the draft order should control xylazine as a class C drug under the MDA.

The order also looks at the entry for methoxphenidine, to add an additional common-use name and its full international standardised name, which will be covered by the order. This does not affect the existing control status of the substance as a class B drug. Instead, it will add clarity on exactly which drug is controlled, given that there are multiple common names.

I turn to the effect of this order. If it is made today, it will make the substances that I have indicated subject to controls under the MDA and associated offences. This will provide enforcement agencies, such as the police, with the appropriate powers to further restrict the supply and general use of the substances that I have mentioned. Unless exempt, these substances are likely also to be subject to the provisions of the Psychoactive Substances Act 2016, on which I fondly remember sitting in Committee in another place for many moons. Once controlled, they will be subject only to the provisions of the MDA and will no longer be covered by the Psychoactive Substances Act.

The MDA contains much higher penalties for the supply of these drugs and provides for a simple possession offence. Those who supply or produce class A drugs could face up to life imprisonment or an unlimited fine, or indeed both. For a class C drug, the penalty could be up to 14 years’ imprisonment or an unlimited fine, or both. Those found in unlawful possession face up to seven years in prison for a class A drug and up to two years in prison for a class C drug, or an unlimited fine, or indeed both.

Therefore, if this order is made, another statutory instrument will have to be introduced later, via the negative resolution procedure. This will seek to make amendments to the associated legislation, namely the Misuse of Drugs Regulations 2001 and, if necessary, the 2015 misuse of drugs designation order. This negative statutory instrument will seek to schedule and designate these substances to ensure that they are appropriately available for legitimate use, which is important for this House to know and consider.

Although all these substances, and the generic definition of nitazenes, have been identified as having no recognised medicinal use in the United Kingdom, xylazine remains a veterinary medicine. As such, this will be the only substance placed under Part 1 of Schedule 4 to the MDR, to enable its continued legitimate use. All others will be listed as Schedule 1 drugs and will require a Home Office-approved licence for research and other special purposes. It is the Government’s intention that these amendments will come into force on the same date as this affirmative order in due course early next year.

I hope that I have not surrounded noble Lords with too much information or too many acronyms, but it is important to note that this draft order encompasses a number of recommendations, all of which have been made by the ACMD following detailed and independent assessment of the harms associated with these substances. Noble Lords will know that drugs can ruin lives and continue to affect society as a whole. This Government are committed to protecting the public against such dangerous substances and ensuring that appropriate controls are in place. I hope that the Grand Committee will agree with the Home Office’s recommendations and this draft order. I beg to move.

[Baroness Doocey (LD)]

My Lords, we accept the recommendation of the advisory council and support the tightening of these regulations. I shall add a couple of comments. In relation to synthetic opioids, given the continual emergence of new individual nitazenes, we are in favour of introducing a generic control for these substances. They can be much more potent than heroin, leaving users at a particularly high risk of accidental overdose. Nitazenes have already cost lives in the UK, and although there is little local evidence of the impact of the other six synthetic opioids named in the order, the potential harm they could wreak is abundantly clear, given the high risk posed for addiction and fatality, as outlined by the Minister.

The need to keep up with organised crime’s ability to synthetise new varieties of opioid is crucial at a time when the UK and European markets are especially vulnerable to their influx, given the noted drop in the supply of heroin and fentanyl. The market is shifting as people seek alternatives, so it is highly likely that the substances named will become much more prevalent. The advisory council’s report calls the individual controlling of these six named synthetic opioids “a short-term approach”. Will the Government consult on the introduction of a generic definition for these substances similar to that for nitazenes?

I also have real concern about the UK’s ability to detect these new substances in a timely fashion. I note that screening and chemical testing for them is extremely limited, that many laboratories do not have the resources routinely to check for them and that they are often not incorporated into police drug tests. Given the damage that we have seen synthetic opioid addiction wreak on parts of the USA, it is of the utmost importance that we have all the warnings we can get of what is emerging on the UK market and where.

The importance of this is underlined by another of the substances we are dealing with today, xylazine. The first UK death in which it was implicated came to light only thanks to the vigilance of a toxicologist who detected it at postmortem because they decided to investigate what they thought were strange results. Internationally, heroin and synthetic opioids such as fentanyl are increasingly being cut with xylazine, and we know it is increasingly present in fatal overdoses in the US where in some states it is present in more than one-quarter of all drug deaths, yet because xylazine is not included in standard UK drug testing we do not know how widespread its use is here. It is a not a nice drug. It leaves people like zombies and its continued use rots their skin from the inside. Back in 2022, there was also apparently no way of recording it in the UK drug deaths database. Is this still the case? Will the Minister address my wider concerns around testing?

The Liberal Democrats do not believe that criminalising individuals for drug possession is the answer, and we will continue to call for a better public health response to tackling the drugs crisis. Will the Government make any additional funding available to enable the consistent national implementation of pre-arrest and pre-prosecution police drug diversion schemes?

--- Later in debate ---

Today, we heard a bit about possible sentencing, but we have also seen more offenders released from our prisons early. What is the Minister’s reflection on the ability to sentence for drugs misuse in that context?

[Lord Hanson of Flint (Lab)]

I am grateful to the noble Baroness, Lady Doocey, and the noble Lord, Lord Sharpe, for their contributions from both Opposition Front Benches.

I will deal initially with the noble Baroness, Lady Doocey. She made an important point about consultation and the further discussions around a potential generic definition for the six synthetic opioids and for nitazenes. She will know that the original order has arisen because of the ACMD’s recommendation of 24 March that consultation be undertaken with various stakeholders. Consultation was undertaken with academia, the chemicals industry and the pharmaceutical industry on the introduction of the generic control in order to cover the points before the Committee today.

Following the consultation, the ACMD recommended that generic control be added to class A of the MDA, consistent with the classification of other potent opioids. We will certainly consider the noble Baroness’s suggestion that it would be appropriate to consult key stakeholders in due course. I assure her that that will be kept under review and that we will rely particularly on the ACMD’s future advice on that generic definition; however, as with the 24 March order, consultation will take place.

The noble Baroness rightly recognised the great harm done, particularly in the United States, by some of the drugs mentioned in this order. She also rightly highlighted the need to monitor drug deaths accordingly. Detections of xylazine in drug-related deaths are now recorded on the drugs death database, which is available through the Office for National Statistics. I accept that that is not necessarily the most user-friendly way of getting those figures, but they are available, open to scrutiny and open to comment from the noble Baroness. The HMG Synthetic Opioids Taskforce is currently overseeing and co-ordinating the Government’s strategic response to the threat of synthetic opioids—and threat there is. The task force will look at the prevalence and harms of xylazine and its co-use with synthetic opioids; I hope that that gives the noble Baroness some reassurance on that point.

The noble Baroness raised the important issue of the public health response. This is a drug response. As the noble Lord, Lord Sharpe, mentioned, there is a criminal justice aspect to that response in today’s order, but it is important that we focus on the public health response as well. The noble Baroness will know that we are currently in the process of carrying out a financial review for 2025-26 and that the Chancellor is in a pre-Budget period, so it is difficult to discuss these matters generally, but I give her this commitment: it is the Government’s firm belief that we need to ensure that we divert people from illegal drugs through interventions, such as drug treatment services, to help reduce drug misuse, drug-related crimes and reoffending.

Before I came to this House or to the other place, I worked as director of a charity dealing with drug and solvent abuse. Interventions are key to prevention, in both family and individual support, by ensuring that they reduce access to drugs and reduce offending accordingly.

We support the use of drug testing on arrest and out-of-court resolutions to ensure that individuals who commit drug-related offences are given the opportunity to change their behaviour. Again, I hope that while this is a drug identification and criminal justice response, there is a wider agenda underneath to examine the points that have been made. I also put it to the noble Baroness that any substance capable of producing a psychoactive effect is likely to be captured by the Psychoactive Substances Act 2016, which will mean that the supply remains unlawful.

I am grateful also for the general support of the noble Lord, Lord Sharpe. He may well, dare I say it, have seen some of the information that relates to this when in a previous Government he held, with some great support, the post that I hold now. He will know that we will examine a range of mechanisms. The points that he raised today are extremely valid and supported, and we will certainly look at them as we take this matter forward. He particularly raised the generic definition of nitazenes. The ACMD has published four addendums to the generic definition and we, and the ACMD, will continue to monitor the position accordingly. If new compounds emerge, self-evidently we, as a Government with the advice of experts, would want to ensure that those were legislated on to protect the public and support individuals, in the same way that the noble Baroness, Lady Doocey, mentioned earlier.

The noble Lord introduced—rather cheekily, if I may say so—the question of whether, if these penalties are approved, as they potentially will be in due course, there will be a potential impact on prison places. I should clarify that that approval will be by the Privy Council. He will know that my right honourable friend Shabana Mahmood, the Lord Chancellor and Secretary of State for Justice, is currently examining mechanisms to ensure that those serving short prison sentences find alternatives to custody in a positive way, while still paying a penalty to society and still being potentially under either house arrest or some other treatment order. That will depend on the reason why they committed offences in the first place.

I reassure the noble Lord that prison will be there for people who deserve it, but that there will be alternative sentences where deemed appropriate by the judiciary. We are trying, with the Ministry of Justice, to expand the potential examination of those issues. The noble Lord will also know that a sentencing review has just been announced under a former Member of Parliament from his own Benches, David Gauke. That will ultimately feed into a justice policy that I hope is fit for the next 10 years, as opposed to the last 14.

I clarify for the Committee that the amendments will come into force on the same date as this affirmative order, early next year. They will go to the Privy Council for approval and, once approved, as I hope they will be by this House as well as the Privy Council, will become law to tackle what are difficult issues, but on which I sense that there is an element of coterminosity between the three speakers in this debate.

Motion agreed.